Delcath Systems posts Q3 2026 results, lifts full‑year revenue guidance
+1 new source since this summary was written
Delcath Systems reported third‑quarter 2026 revenue of $35.1 million, a 70%‑71% year‑over‑year increase, and net income of $7.0 million. Gross margin rose to 89% and adjusted EBITDA to $11.5 million. The company raised its 2026 revenue outlook to $115 million‑$117 million and said HEPZATO KIT volume grew about 72% YoY, with 33 active treatment centers and a target of at least 36 by year‑end.
Why it matters
The higher guidance expands the revenue runway for investors, while the strong margin and cash flow improve the company’s financial flexibility. Analysts such as BTIG upgraded their price target, reflecting expectations of continued growth.
Key facts
- 1Q3 2026 revenue was $35.1 million, up from $20.6 million a year earlier tradingview.com
- 2Net income for the quarter was $7.0 million, versus $0.8 million in Q3 2025 tradingview.com
- 3Gross margin for the quarter was 89% tradingview.com
- 4Adjusted EBITDA was $11.5 million tradingview.com
- 5Full‑year 2026 revenue guidance was raised to $115 million‑$117 million tradingview.com
- 6HEPZATO KIT volume grew approximately 72% year‑over‑year tradingview.com
Summary written by AlphAI AI Desk from 14 of 14 sources. Not investment advice. Figures are as stated by the linked sources.